Enliven Therapeutics (ELVN) Operating Expenses (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Operating Expenses data on file, last reported at $27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 12.21% year-over-year to $27.8 million; the trailing twelve-month figure through Mar 2026 stood at $115.8 million (up 5.01% YoY), and the FY2025 full-year result was $119.7 million, up 14.45% from the prior year.
• Operating Expenses declined to $27.8 million in Q1 2026, from $34.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $34.3 million in Q4 2025 to a low of $8.7 million in Q1 2022.
• A 5-year average of $22.0 million and a median of $24.6 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses plunged 31.54% in 2022 and surged 123.64% in 2023, its largest moves.
• Tracing ELVN's Operating Expenses over 5 years: stood at $10.2 million in 2022, then soared by 123.64% to $22.7 million in 2023, then climbed by 18.33% to $26.9 million in 2024, then climbed by 27.47% to $34.3 million in 2025, then retreated by 18.85% to $27.8 million in 2026.
• Business Quant data shows ELVN's Operating Expenses at $27.8 million in Q1 2026, $34.3 million in Q4 2025, and $25.1 million in Q3 2025.